bioRxiv
May 18, 2026
Kyna Conn, Ngok Wong, Serenay Sunnetci et al.
preprint
Abstract Psilocybin has emerged as a promising therapeutic agent for psychiatric disorders characterised by cognitive rigidity and disrupted reward processing, including anorexia nervosa. While its pro-cognitive effects have been mechanistically probed almost exclusively through serotonin receptor subtype antagonism, the downstream contributions of dopaminergic systems to these outcomes remain...
Journal of Psychoactive Drugs
May 18, 2026
Kevin H. Yang, Miranda Rasmussen, Kush V. Bhatt et al.
1 citation
Recent literature suggests potential associations between hallucinogen use and valvular heart disease (VHD) due to prolonged activation of serotonin 5-HT2B receptors, which may lead to valvular fibrosis – a condition also linked to drugs including fenfluramine and pergolide. Despite these concerns, epidemiological studies exploring this association are lacking. This exploratory analysis...
Zenodo (CERN European Organization for Nuclear Research)
May 17, 2026
Tenzin Trepp
preprint
Emerging research in contemplative science and psychedelic neuroscience suggests that deeply entrenched patterns of selfhood and cognition—often associated with mental disorders like depression—can be profoundly altered through both meditative practice and pharmacological intervention. This paper presents a neuroconstructivist framework for understanding how deep meditation and dissociative...
DIGITAL.CSIC (Spanish National Research Council (CSIC))
May 12, 2026
Javier Calleja‐conde, Víctor Echeverry‐alzate, Marina Sanz-Sancristóbal et al.
Parkinson's disease is a progressive neurodegenerative disorder with increasing global prevalence, primarily driven by population ageing. A hallmark of the disease is the degeneration of nigrostriatal dopaminergic neurons, accompanied by marked activation of glial cells and a sustained neuroinflammatory response. Current pharmacological treatments are limited to symptomatic relief and do not...
Experimental Neurology
May 12, 2026
Javier Calleja‐conde, Víctor Echeverry‐alzate, Marina Sanz-Sancristóbal et al.
Parkinson's disease is a progressive neurodegenerative disorder with increasing global prevalence, primarily driven by population ageing. A hallmark of the disease is the degeneration of nigrostriatal dopaminergic neurons, accompanied by marked activation of glial cells and a sustained neuroinflammatory response. Current pharmacological treatments are limited to symptomatic relief and do not...
ACS Medicinal Chemistry Letters
May 7, 2026
Ram W. Sabnis, Anika R. Sabnis
Provided herein are novel tricyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.
ACS Chemical Neuroscience
May 6, 2026
Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.
Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...
Neurochemical Research
May 6, 2026
Oyedayo Phillips Akano, Goodness Olatinwo, Moses Agbomhere Hamed et al.
3,4-Methylenedioxymethamphetamine (MDMA), widely misused for its euphoric and stimulant properties, induces overt neurotoxicity in rodents and non-human primates and is associated with profound neurochemical and structural brain alterations. Its deleterious effects are primarily mediated through oxidative stress, neuroinflammatory responses, and apoptotic pathways. Glutathione, a crucial...
bioRxiv
May 4, 2026
Tomás Ariel D’amelio, Tomás Gil Garbagnoli, Jerónimo Rodríguez Cuello et al.
preprint
ABSTRACT Serotonergic psychedelics induce altered states of consciousness characterised by profound changes in emotional experience. Although psychedelics modulate autonomic arousal, sympathetic engagement during their affective effects remains poorly characterised. We recorded cardiac, electrodermal, and respiratory activity in 19 participants following inhalation of 20 or 40 mg of freebase...
International Journal of Pharmacology and Clinical Research
May 1, 2026
Jyothsna Kuralla, Harsh Chaturvedi
Major depressive disorder (MDD) remains a global health burden, with over 60% of patients failing to respond adequately to current treatments. Treatment-resistant depression (TRD), a form of MDD, highlights the urgent need for mechanistically novel antidepressants. Psychoplastogens—a class of fast-acting compounds that promote neuroplasticity—are emerging as promising alternatives to...